Group 1 - The company *ST Dongjing (002199.SZ) has stated that it does not currently sell products directly to EU countries [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 順豪物業投資有限公司 (於香港註冊成立之有限公司) | | | 呈交日期: | 2025年12月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 2 頁 共 10 頁 v 1.1.1 FF301 III.已發行股份及/或庫存股份變動詳情 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00219 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | ...

Group 1 - The core point of the article is that ST Zhengtong (002197) has applied to revoke its other risk warnings after completing the necessary financial report restatements and after a twelve-month period since the regulatory penalty [1] - As of November 28, 2025, ST Zhengtong's stock closed at 10.47 yuan, down 0.76% from the previous trading day, with a total market value of 6.432 billion yuan [1] - The company reported a trading volume of 1.05 billion yuan and a turnover rate of 1.87% on the same day [1] Group 2 - The company is currently involved in 754 investor compensation cases, with a total amount of approximately 69.2534 million yuan, and has not yet recognized any expected liabilities for these cases [1] - The application to revoke the risk warning is subject to review by the Shenzhen Stock Exchange, which introduces an element of uncertainty [1]

格隆汇11月28日丨ST证通(002197.SZ)公布，公司对照《深圳证券交易所股票上市规则（2025年修 订）》逐项排查，不存在9.8.1条所列示的其他风险警示的情形，同时也符合9.8.8条关于申请撤销其他风 险警示的条件。公司于2025年11月28日召开第七届董事会第四次（临时）会议审议通过了《关于申请撤 销其他风险警示的议案》。 ...

Core Points - After nearly six months of investigation, Jiaying Pharmaceutical received a total fine of 4.9 million yuan for information disclosure violations, along with warnings and regulatory actions from the Guangdong Securities Regulatory Bureau and the Shenzhen Stock Exchange [2][5][9] Group 1: Administrative Penalties - The Guangdong Securities Regulatory Bureau issued an administrative penalty decision, imposing a fine of 1.5 million yuan on Jiaying Pharmaceutical, and additional fines on key executives: 1.6 million yuan on Chairman Li Neng, 1 million yuan on General Manager You Yongping, and 800,000 yuan on former CFO Shi Junping, totaling 4.9 million yuan [5][8] - Warnings and regulatory letters were issued to Jiaying Pharmaceutical and its executives, including Li Neng, You Yongping, Shi Junping, and former board secretary Xiao Qiaoxia [5][9] Group 2: Violations and Findings - The investigation revealed that Li Neng, as the actual controller of Hunan Yaojun Pharmaceutical Co., engaged in improper fund transfers between Jiaying Pharmaceutical and its related party, resulting in a total of approximately 220 million yuan in transactions, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [7][8] - Jiaying Pharmaceutical failed to disclose related party transactions in a timely manner, including transactions with Gonghe Pharmaceutical, which involved approximately 8.76 million yuan, representing 1.15% of the company's latest audited net assets [7][8] Group 3: Additional Regulatory Actions - The Shenzhen Stock Exchange issued a public reprimand against Jiaying Pharmaceutical and its executives, citing violations related to non-operating fund transfers and improper financial assistance [12][13] - Jiaying Pharmaceutical provided a total of 65 million yuan in financial assistance to three non-related companies, with a maximum daily balance of 40 million yuan, which accounted for 5.24% of the company's latest audited net assets [12]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 順豪物業投資有限公司 (於香港註冊成立之有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00219 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 579,753,289 | | | | 579,753,289 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 579,753,289 | | 0 | | 579,75 ...

Core Points - ST Zhengtong (002197.SZ) released its Q3 2025 report on October 30, 2025 [1] - As of October 29, 2025, there are 2 institutional investors holding shares in ST Zhengtong, totaling 20 million shares, which accounts for 3.26% of the total share capital [1] - The institutional investors include Zhuhai Abama Private Fund Investment Management Co., Ltd. - Abama Yuanxiang Dividend No. 83 Private Securities Investment Fund and Xuanyuan Private Fund Investment Management (Guangdong) Co., Ltd. - Xuanyuan Kexin No. 43 Private Securities Investment Fund, with a combined holding ratio of 3.26% [1]

Market Overview - On October 16, the three major A-share indices opened lower, with the Shanghai Composite Index down 0.29%, the Shenzhen Component Index down 0.42%, and the ChiNext Index down 0.58%. However, by the time of reporting, all three indices turned positive, with the Shanghai Composite Index up 0.18%, the Shenzhen Component Index up 0.38%, and the ChiNext Index up over 1% [1]. Sector Performance - The insurance, military equipment restructuring concept, and education sectors saw the largest gains, while the wind power equipment, gas, and controllable nuclear fusion sectors experienced the largest declines [4]. - The insurance sector increased by 2.45%, military equipment restructuring concept by 1.73%, and education by 1.49% [5]. Individual Stock Highlights - Chengfei Integration (002190) opened with a significant surge, hitting the daily limit and closing at 47.1 yuan per share, with a trading volume exceeding 1.1 billion yuan [5][6]. - The stock's market capitalization is approximately 16.896 billion yuan, with a price-to-earnings ratio of 10.00% and a trading volume ratio of 5.29 [6]. - Sanhua Intelligent Control saw a nearly 5% drop at the open, which narrowed to a 2.99% decline after the company clarified that rumors regarding substantial robot orders were untrue [7][8].

Core Points - Ruiyi Group has been named by regulators again for suspected violations of information disclosure, leading to an investigation by the China Securities Regulatory Commission (CSRC) [2][5] - The company has faced multiple regulatory warnings and penalties in recent years, including issues related to insufficient impairment provisions for long-term equity investments and undisclosed related party transactions [2][8] - In 2024, Ruiyi Group reported a net loss of 577 million yuan, while its controlling shareholder, Ruiyi Technology, is embroiled in contract disputes and has all its shares pledged and frozen [2][11] - The company's stock price hit the daily limit down on October 15, 2024, following the announcement of the investigation [2] Financial Performance - For the fiscal year 2024, Ruiyi Group achieved a revenue of 449 million yuan, with a net profit attributable to shareholders of -577 million yuan [11] - In the first half of 2025, the company reported a revenue of 154 million yuan, a year-on-year decline of 32.25%, and a net profit of -95.73 million yuan, representing a 105% increase in losses compared to the previous year [12] - The company’s total assets decreased by 2.39% year-on-year, while net assets attributable to shareholders fell by 14.34% [12] Management and Governance Issues - Ruiyi Group's actual controller, Qiu Yafu, has been identified as a person of untrustworthiness and is restricted from high consumption, which raises concerns about the company's governance [2][13] - Qiu Yafu transferred the position of chairman to his daughter, Qiu Chenran, amid ongoing governance challenges and regulatory scrutiny [8][19] - The auditing firm expressed reservations about the company's financial reports, particularly regarding a long-term equity investment valued at approximately 300 million yuan [10] Shareholder and Credit Risks - Ruiyi Technology, the controlling shareholder, has all its shares pledged and frozen, which poses risks to the stability of the company's control and future development [13][19] - The controlling shareholder's credit crisis and the inability to provide support may adversely affect the company's financing capabilities and market reputation [19]

Core Viewpoint - Ruiyi Group has been named by regulators again for suspected violations of information disclosure, leading to an investigation by the China Securities Regulatory Commission (CSRC) [2][5]. Group 1: Regulatory Issues - Ruiyi Group announced on October 14 that it is under investigation for suspected violations of information disclosure laws, marking another instance of regulatory scrutiny [5]. - The company has faced multiple administrative penalties and warnings in recent years, including issues related to insufficient impairment provisions for long-term equity investments and undisclosed related party transactions [2][7]. Group 2: Financial Performance - In 2024, Ruiyi Group reported a net loss attributable to shareholders of 577 million yuan, while its total revenue was 449 million yuan [2][11]. - The company's financial situation continued to deteriorate into 2025, with a 32.25% year-on-year decline in revenue for the first half of the year, amounting to 154 million yuan, and a net loss of approximately 95.73 million yuan, which is a 105% increase in losses compared to the previous year [11][12]. Group 3: Shareholder and Management Issues - Ruiyi Group's controlling shareholder, Ruiyi Technology, has all its shares pledged and frozen due to contract disputes, and both the shareholder and the actual controller, Qiu Yafu, have been listed as untrustworthy individuals [2][13]. - Qiu Yafu, previously known as the "Godfather of Chinese Luxury," has faced significant financial and legal challenges, including a total unpaid balance exceeding 7 billion yuan from various court cases [16][22].